Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Huahai PharmaceuticalProduct approvals

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

ADC / XDCCancer

CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

Clinical trial approval / initiationHengrui Pharmaceuticals

Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

ADC / XDCAkeso Biopharma

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Show More